Humacyte (NASDAQ:HUMA) Shares Cross Above 50 Day Moving Average – What’s Next?

Humacyte, Inc. (NASDAQ:HUMA)’s stock price crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $0.49 and traded as high as $0.5970. Humacyte shares last traded at $0.59, with a volume of 15,631,458 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Friday, October 2nd. Cantor Fitzgerald set a $1.00 price objective on Humacyte in a research note on Thursday. BTIG Research reaffirmed a “buy” rating and set a $2.00 price objective on shares of Humacyte in a report on Tuesday. HC Wainwright reiterated a “buy” rating on shares of Humacyte in a research report on Friday, October 16th. Finally, Wall Street Zen lowered Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.48.

Humacyte Stock Performance

The business has a fifty day simple moving average of $0.49 and a 200 day simple moving average of $0.78. The company has a current ratio of 3.34, a quick ratio of 5.74 and a debt-to-equity ratio of 3.65.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The company had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $1.04 million. Humacyte had a negative return on equity of 612.88% and a negative net margin of 3,955.05%. As a group, equities research analysts forecast that Humacyte, Inc. will post -0.40 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUMA. Alyeska Investment Group L.P. purchased a new stake in shares of Humacyte during the second quarter worth about $4,700,000. BlackRock Inc. acquired a new position in shares of Humacyte in the second quarter valued at approximately $3,777,000. GSA Capital Partners LLP purchased a new position in shares of Humacyte during the second quarter valued at approximately $785,000. HBK Investments L P purchased a new position in shares of Humacyte during the second quarter valued at approximately $617,000. Finally, Wealth Effects LLC acquired a new stake in Humacyte during the second quarter worth approximately $542,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.